Thursday Aug 14
Stemline Therapeutics Provides Second Quarter 2014 Financial Results and Corporate Update
Stemline Therapeutics, Inc. , a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells and tumor bulk, today provided a corporate update and reported financial results for the quarter ended June 30, 2014.
Stemline Therapeutics Announces Opening of SL-401 Corporate IND and...
Stemline Therapeutics, Inc. announced today the opening of its SL-401 Investigational New Drug and initiation of a broad clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia .